Analyst Ratings for Mineralys Therapeutics, Inc. (MLYS)
MLYS Rating Summary
MLYS Price Target Summary
- Highest: $56.00 (H.C. Wainwright)
- Lowest: $29.00 (UBS)
- Average: $45.00
* Over Last 12-Mos
Overall Rating:
BUY
Rating Trend:
Avg. $ Target:
$45.00 (+121.7%)
* Over Last 12-Mos
Rating Score: 8.3 / 10
Percentile Rank: 85%
Avg. $ Target:
$45.00 (+121.7%)
* Over Last 12-Mos
Rating Score: 8.3 / 10
Percentile Rank: 85%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 10/12/2026 | UBS | Alice Nettleton | New Coverage | Neutral (N/A) |
29.00 (N/A) |
22.38 (20.30) |
-9.29% | Details |
| 4/27/2026 | TD Cowen | Tara Bancroft | New Coverage | Buy (N/A) |
N/A (N/A) |
27.51 (20.30) |
-26.21% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
